News | July 17, 2007

Non-Fasting Triglyceride Levels Predict Risk of Cardiovascular Events Among Women

July 18, 2007 - In a related study of over 25,000 initially healthy women, higher triglyceride levels measured after not fasting is associated with an increased risk for cardiovascular events, but his association was not found for triglyceride levels measured after fasting, according to a study in the July 18 issue of JAMA.

Sandeep Bansal, M.D., of Brigham and Women’s Hospital and the Harvard School of Public Health, Boston, and colleagues conducted a study to determine the association of triglyceride levels (fasting vs. nonfasting) and risk of future cardiovascular events. The study included 26,509 initially healthy U.S. women (20,118 fasting and 6,391 nonfasting) participating in the Women’s Health Study, enrolled between November 1992 and July 1995. Triglyceride levels were measured in blood samples obtained at time of enrollment.

During a median (midpoint) follow-up of 11.4 years, 1,001 participants experienced a new cardiovascular event (including 276 nonfatal heart attacks, 265 ischemic strokes, 628 coronary revascularizations, and 163 cardiovascular deaths).

"In this large-scale, prospective cohort of initially healthy U.S. women, we observed that higher nonfasting triglyceride levels were strongly associated with an increased risk of future cardiovascular events, independent of baseline cardiac risk factors, levels of other lipids, and markers of insulin resistance. In contrast, fasting triglyceride levels showed little independent association with cardiovascular events. Associations were particularly strong among individuals who had their blood drawn 2 to 4 hours after a meal, and this relationship weakened as more time elapsed postprandially," the authors write.

"Our observations may have implications for the design and conduct of clinical trials evaluating triglyceride-lowering medications. To date, almost all clinical trials of pharmaceutical agents targeting triglyceride levels have relied on fasting levels as inclusion criteria. However, if levels measured in the fasting state are not the best marker for the atherogenicity associated with hypertriglyceridemia, then it is possible that these trials might have targeted the wrong patient populations. By contrast, previous studies have demonstrated the benefits of several classes of drugs on postprandial elevations in triglyceride levels. Thus, based on the data presented here, future end point reduction trials of triglyceride-lowering agents might consider participant inclusion on the basis of nonfasting rather than fasting triglyceride levels."

Source: (JAMA. 2007;298(3):309-316. Available pre-embargo to the media at www.jamamedia.org)

For more information: www.pubs.ama-assn.org/

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init